Jeremy Moad, MD
Pulmonary Disease · Edmond, OKNPI 1134325608
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 226 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 16.3% — the pattern of someone who eats at a lot of different presentations.
Across 226 payments — averaging $18.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$692
- AstraZeneca$552
- GSK$364
- Sanofi$286
- Amgen$282
- Actelion Pharmaceuticals US, Inc.$280
- plus $2K from 22 others
What the payments were for
- Food & beverage$4,244100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 35 | $692 |
| AstraZeneca | 27 | $552 |
| GSK | 26 | $364 |
| Sanofi | 12 | $286 |
| Amgen | 13 | $282 |
| Actelion Pharmaceuticals US, Inc. | 15 | $280 |
| Regeneron Healthcare Solutions, Inc. | 9 | $233 |
| Baxter Healthcare | 9 | $207 |
| Inogen, Inc. | 17 | $199 |
| Fisher & Paykel Healthcare Inc | 6 | $164 |
| CSL Behring | 7 | $126 |
| Insmed, Inc. | 4 | $112 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $99 |
| Sunovion Pharmaceuticals Inc. | 11 | $98 |
| Pfizer | 6 | $91 |
| Novartis | 6 | $87 |
| Harmony Biosciences LLC | 3 | $61 |
| Vifor Pharma, Inc. | 2 | $54 |
| Merck | 3 | $49 |
| Johnson & Johnson | 2 | $39 |
| United Therapeutics Corporation | 1 | $31 |
| Electromed, Inc. | 1 | $29 |
| Mylan Specialty L.p. | 2 | $25 |
| Advanced Respiratory, Inc | 1 | $24 |
| Viatris Specialty LLC | 1 | $20 |
| Chiesi USA, Inc. | 1 | $15 |
| Grifols USA, LLC | 1 | $13 |
| Circassia Inc. | 1 | $12 |
How this compares
$4,244 in reported general payments places this provider in the 60th percentile of 133 pulmonary disease providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 49 | $684,769 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 617 | $506,134 |
| Breo ElliptaFluticasone/Vilanterol | 120 | $68,901 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 51 | $48,423 |
| Dupixent PenDupilumab | 13 | $46,956 |
| Spiriva RespimatTiotropium Bromide | 57 | $34,954 |
| EliquisApixaban | 30 | $24,273 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 24 | $18,670 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 19 | $15,418 |
| SymbicortBudesonide/Formoterol Fumarate | 52 | $13,178 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 80 | $11,686 |
| Spiriva HandihalerTiotropium Bromide | 14 | $10,213 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 255 | $8,428 |
| DuleraMometasone/Formoterol | 14 | $4,873 |
| BreynaBudesonide/Formoterol Fumarate | 16 | $3,086 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Combivent Respimat, Stiolto Respimat | $692 | $753,811149 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $364 | $575,035737 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $552 | $61,602103 claims |
| PfizerEliquis | $91 | $24,27330 claims |
| MerckDulera | $49 | $4,87314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 133 pulmonary disease providers in Oklahoma.
Other pulmonary disease in Edmond
- Michael HullEdmond$642K
- John KingreyOklahoma City$332K
- Jennifer BierachTulsa$141K
- Hassan AbouhouliTulsa$103K
- Fawad ChaudryOklahoma City$80K
- Maroun TawkOklahoma City$62K
- Grace KennedyTulsa$57K
- Nancy NagleOkc$51K
- Dennis ParkerOkc$46K
- Walter BoomerTulsa$43K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.